美国生物技术公司莫德纳（Moderna, Inc.，股票代码：MRNA）今日盘中股价大涨5.55%，引发市场广泛关注。截至发稿，该股报26.96美元/股，成交量269.066万股，换手率0.70%，振幅3.58%。
莫德纳成立于2010年，是mRNA技术的领先企业之一。公司因其COVID-19疫苗而广为人知，该疫苗于2020年12月在美国获得批准。截至2024年9月，莫德纳拥有40个处于临床试验阶段的mRNA开发候选物，涵盖传染病、肿瘤学、心血管疾病和罕见遗传病等多个治疗领域。尽管公司最近的财报显示净亏损9.71亿美元，但其广泛的研发管线和mRNA技术的潜力似乎仍然吸引了投资者的兴趣。
值得注意的是，在所有28家参与评级的机构中，21%的券商给予买入建议，64%的券商给予持有建议，15%的券商给予卖出建议。这种相对积极的分析师评级可能也是推动股价上涨的因素之一。尽管如此，投资者仍需谨慎，因为生物技术行业的投资通常伴随着较高的风险和不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.